- Home
- ANNX vs NUS Comparison
ANNX vs NUS Comparison
Compare ANNX & NUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANNX
- NUS
- Stock Information
- Founded
- ANNX 2011
- NUS 1984
- Country
- ANNX United States
- NUS United States
- Employees
- ANNX N/A
- NUS N/A
- Industry
- ANNX Biotechnology: Pharmaceutical Preparations
- NUS Other Pharmaceuticals
- Sector
- ANNX Health Care
- NUS Health Care
- Exchange
- ANNX Nasdaq
- NUS Nasdaq
- Market Cap
- ANNX 362.4M
- NUS 321.6M
- IPO Year
- ANNX 2020
- NUS 1996
- Fundamental
- Price
- ANNX $1.93
- NUS $7.28
- Analyst Decision
- ANNX Strong Buy
- NUS Hold
- Analyst Count
- ANNX 7
- NUS 2
- Target Price
- ANNX $15.80
- NUS $6.88
- AVG Volume (30 Days)
- ANNX 1.7M
- NUS 648.5K
- Earning Date
- ANNX 03-03-2025
- NUS 05-07-2025
- Dividend Yield
- ANNX N/A
- NUS 3.28%
- EPS Growth
- ANNX N/A
- NUS N/A
- EPS
- ANNX N/A
- NUS N/A
- Revenue
- ANNX N/A
- NUS $1,732,084,000.00
- Revenue This Year
- ANNX N/A
- NUS N/A
- Revenue Next Year
- ANNX N/A
- NUS N/A
- P/E Ratio
- ANNX N/A
- NUS N/A
- Revenue Growth
- ANNX N/A
- NUS N/A
- 52 Week Low
- ANNX $1.93
- NUS $5.95
- 52 Week High
- ANNX $7.85
- NUS $14.00
- Technical
- Relative Strength Index (RSI)
- ANNX 30.11
- NUS 45.42
- Support Level
- ANNX $2.18
- NUS $6.79
- Resistance Level
- ANNX $2.75
- NUS $8.35
- Average True Range (ATR)
- ANNX 0.25
- NUS 0.35
- MACD
- ANNX -0.01
- NUS -0.12
- Stochastic Oscillator
- ANNX 0.00
- NUS 30.50
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.
About NUS Nu Skin Enterprises Inc.
Nu Skin Enterprises Inc is a health and beauty direct-selling company. It has two primary product categories: beauty products and wellness products. The company develops and distributes nutritional, weight-management products, and food supplements under the Nu Skin and Pharmanex brands, respectively. The company has operations internationally, in more than 50 countries across the Americas, Europe, and the Asia-Pacific.